Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

double-blind, multi-center trial with an open label extension. There were a total of 132 patients randomized in the trial. Eighty-eight patients received escalating doses of pagoclone from 0.3 mg to 0.6 mg per day. Forty-four patients received placebo. Seventy-nine percent of the patient population was male, which is reflective of the gender distribution of this disorder. Although open label treatment is not blinded, patients and investigators remained blinded to the original treatment allocation during the 8-week double-blind phase.

More than 70% of the 119 patients who entered the open label phase of the EXPRESS trial were included in the three month open label data being presented at NCDEU.

Study Results

The primary endpoints evaluated in the double-blind, phase of the study were the Frequency and Duration Subscale of the Stuttering Severity Instrument Version 3 (SSI-3), the Stuttering Severity Scale (SEV) and the Subjective Screening of Stuttering (SSS) Severity Subscore. Given that this was an exploratory study, pre-specified analyses utilized 1-tailed tests of significance.

The SSI-3 is a validated measure of stuttering. During study visits at week 4 and week 8, patients were videotaped while engaged in both a conversational and reading task. The videotapes were analyzed and scored at a central laboratory. Raters were blinded with regard to treatment and visit. The frequency and duration subscales were calculated by measuring the proportion of syllables stuttered compared to syllables spoken and the length of time of each stuttering block or event. The variability of stuttering naturally tends to wax and wane over time. Accordingly, two data points were collected prior to treatment and two data points were collected while on treatment at week 4 and week 8 to determine the on-treatment effect of pagoclone. The on-treatment effect of pagoclone was shown to produce a statistically significant reduction in the frequency and duration of
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
(Date:9/19/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 19, ... company focused on cloud-based drug design and development, ... strategy. The company,s mission is to design new ... Phase 1 and 2 partners to further their ... enhance its portfolio investments. To support this business ...
(Date:9/19/2014)... DUBLIN , Sept. 19, 2014 Research ... "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) ... For the purposes of this report, the human ... The human microbiome market is expected to be ... grow at a CAGR of 22.3% within the forecast period ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) will ... community on Thursday, December 8, 2011 from 8:00 a.m. ... New York City.  Members of BioMarin,s management team and ... product portfolio and advancements in the research and development ...
... 17, 2011 Eli Lilly and Company (NYSE: ... more than $4 million in additional funding to the ... to continue its early phase drug discovery efforts focused ... against tuberculosis, including multidrug-resistant strains known as MDR-TB. In ...
Cached Medicine Technology:BioMarin to Host a Research and Development Day on December 8th 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 2Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 3Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies 4
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... 21, 2014 The Illinois Joining ... host a statewide symposium ( tinyurl.com/ILBHC14 ) focused ... their Families. Sponsored by the VNA Foundation, Thresholds, ... Grant, and Health & Disability Advocates, the symposium ... Hilton Hotel in Springfield, IL. The symposium ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... implements and supports electronic medical records (EMR) and ... from federal healthcare legislation during the past five ... so during the five years to 2019. The ... Health Act established Medicare and Medicaid incentives to ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2
... million, Five-year Grant, from New York State Department of,Health, ... Lead,Poisoned, NEW YORK, Feb. 11 The Lead ... Montefiore,(CHAM) has been named one of three State Regional ... healthcare delivery for children and,pregnant women with elevated blood ...
... Part of MedCath,s Growth Plans, CHARLOTTE, N.C., Feb. ... physician partners today announced plans to double,the number of ... a 120-bed acute care and heart hospital., The ... into 60 inpatient beds, which will be used to ...
... from the UC Davis M.I.N.D. Institute shows that an ... be linked with the repetitive behavior also called ... studies are needed to confirm the outcome, this result ... prenatal period could be a causal factor for the ...
... SOUTH SAN FRANCISCO, Calif., Feb. 11 ... SpA have announced an agreement granting,an exclusive ... distribution of,Anesiva,s Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... France,Germany, Netherlands, Belgium and Luxembourg. Under the ...
... Unlike other epilepsy meds, Trileptal was no better than ... -- The epilepsy drug oxcarbazepine (Trileptal) does not seem ... finds. , Migraines affect more than 28 million Americans, ... effective in preventing these severe headaches. For this reason, ...
... American Academy of ... Dermatology, ... that validates the benefits of alpha-hydroxy acid (AHA),at- home peels in ... as lasers and microdermabrasion. The,data were highlighted in the Poster Session ...
Cached Medicine News:Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 2Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 3Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 2Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 3Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
This is a 3D transducer for endovaginal imaging in OB/GYN....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Medicine Products: